R. Alan B. Ezekowitz

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Children's Hospital Corp. engages in the provision of pediatric care services. It offers acupuncture, angioplasty, antibiotic allergy testing, audiogram, baclofen pump, biochemical genetic testing, blended diet, bone scan, brain scan, breast augmentation surgery, cardiac catheterization, cardiac MRI in children, chest reconstruction surgery, and CO2 laser treatment. The company was founded by Francis Henry Brown in 1869 and is headquartered in Boston, MA.

Entomed SA discovers and develops novel medicines derived from insects. It discovers and develops new drugs derived from the biology of insects with a focus on their immune response. Entomed's technology is based on the scientific work carried out by Prof. Jules A. Hoffmann's world leading team in the CNRS Institute of Molecular and Cellular Biology (IBMC) in Strasbourg. The company was founded in 1999 and is headquartered in Illkirch-Graffenstaden, France.

Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark.